Machine-learning-guided peptide design yielded non-hemolytic anticancer candidates
A recurrent neural network generated peptide sequences and classified predicted activity and hemolysis; a genetic-algorithm route also generated analogues. After sequence and physicochemical filters, researchers synthesized and tested 33 peptides. The paper reports 11 active anticancer peptides in its cell assays, four non-hemolytic under its red-cell assay. These in-vitro results do not establish cancer-cell specificity, clinical safety or therapeutic efficacy. A related 2020 modeling paper is separate from this experimental study; no claim of absolute sequence novelty is made.
Technology: Generative recurrent neural network, genetic algorithm, and recurrent-neural-network activity and hemolysis classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The abstract reports that 33 peptides were experimentally evaluated, 11 were active in anticancer cell assays, and four of the active peptides were non-hemolytic in the reported assays.
- Still unknown: In-vitro activity and red-cell hemolysis do not establish cancer-cell specificity, clinical safety or treatment efficacy. Detailed potency measurements and absolute sequence novelty were not reassessed in this bounded review.
- AI role: RNN and genetic-algorithm generation with RNN activity and hemolysis classifiers guided peptide selection for synthesis and testing.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/35880810/ · https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.202200291
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary publisher metadata and primary PubMed abstract/affiliation block; full PMC endpoint returned a browser verification challenge in this review..
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.